Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)
Capivasertib (AZD5363) 是一种强效口服泛 AKT 抑制剂，用于治疗复发或难治性 B 细胞非霍奇金淋巴瘤患者的疗效和安全性 (CAPITAL)
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-25-2239
Hodson, Daniel J; Shouse, Geoffrey; Shin, Ho-Jin; Salar, Antonio; Bobillo, Sabela; Ribrag, Vincent; Macpherson, Nicol A; Cordoba, Raul; Kim, Jin Seok; Guidez, Stephanie; Herrera, Alex F; Morschhauser, Franck; Colton, Dachelle; Izuzquiza, Macarena; Sambamurthy, Nisha; Munugalavadla, Veerendra; Vicente, Sergio; Gorgun, Gullu; Chen, Robert; Younes, Anas; Wang, Michael L
